Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 6/20 | 0.34 |
| ▸ | MMP3 | P08254 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6463625 | 0.84 | KCNJ6 (0.36) | EPHX2KMT2AFAAHSMN1; SMN2MMP2 | |
| SCHEMBL7044868 | 0.83 | LMNA (0.37) | EPHX2KMT2ASMN1; SMN2MMP2MMP3 | |
| SCHEMBL7182965 | 0.76 | KMT2A (0.36) | EPHX2KMT2AFAAHSMN1; SMN2HPGD | |
| SCHEMBL7047004 | 0.75 | MAPT (0.34) | KMT2AFAAHSMN1; SMN2NPC1RAB9A | |
| SCHEMBL6462679 | 0.75 | FAAH (0.37) | EPHX2KMT2AFAAHSMN1; SMN2HPGD | |
| SCHEMBL7044254 | 0.72 | KMT2A (0.42) | KMT2AHPGDRAB9A | |
| SCHEMBL7048374 | 0.71 | POLB (0.38) | EPHX2PSMB5 | |
| SCHEMBL6464160 | 0.69 | LMNA (0.39) | EPHX2KMT2AFAAHSMN1; SMN2NPC1 | |
| SCHEMBL6467251 | 0.64 | CTSS (0.46) | FAAH | |
| SCHEMBL5522925 | 0.64 | EPHX2 (0.54) | EPHX2KMT2ASMN1; SMN2NPC1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | EPHX2 696/4885KMT2A 3705/4885FAAH 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.